MeiraGTx Holdings plc
MGTXHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeMeiraGTx Holdings plc, a clinical-stage genetic medicines company, focusing on developing treatments for patients with serious diseases. The $1.15B market capitalization puts MGTX squarely in small-cap range for its industry. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases; neurodegenerative diseases; and xerostomia.
Market Cap
$1.15B
Beta
1.21
P/E (TTM)
—
P/E (Fwd)
-9.10
EPS (TTM)
$-1.49
EPS (Fwd)
$-1.37
ROE
—
ROA
-28.1%
Cash
$71.5M
Total Debt
$87.5M
Free CF
$45.0M
52W Change
44.3%
Annual Financials
Cash vs Debt
MeiraGTx Holdings plc carries $87.5M in total debt against $71.5M in cash reserves — debt is modestly above the cash position. Managing this leverage effectively will be important for long-term financial stability. The company generates $45.0M in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. Revenue has grown from $15.9M (2022) to $81.4M (2025), reflecting a 411% increase over the period.
As with any equity investment, MGTX carries market risk, sector-specific risk, and company-specific risk that investors should evaluate in the context of their own portfolios. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for MeiraGTx Holdings plc and its sector.